OMAHA, Neb. (Aug. 6, 2010)—UNeMed Corporation has made progress in its efforts to enforce its intellectual property directed to creatine ethyl ester (CEE) used as a nutritional supplement. On April 1, 2010, the United States International Trade Commission issued exclusion and cease and desist orders against the four remaining respondents in Certain Products Advertised as Containing Creatine Ethyl Ester, 337-TA-679. The period of Presidential review of those orders expired on May 31, 2010 with no modifications being made to those orders. Thus, the respondents are no longer permitted either to import their products falsely advertised as containing creatine ethyl ester, or to sell any such products that have already been imported into the United States.
UNeMed has also concluded a license agreement with Bio-Engineered Supplements & Nutrition, Inc. (BSN) of Boca Raton, Florida for all of UNeMed’s worldwide issued patents directed to creatine ethyl ester. BSN is a major supplier of nutritional supplements in the United States and around the world.
Finally, UNeMed continues to pursue its remedies in New Zealand for patent infringement against Punch Supplements, an online seller of nutritional supplements in that country. UNeMed is evaluating its options to pursue similar remedies around the world against other, similar companies.
UNeMed Corporation is the technology transfer leader for the University of Nebraska Medical Center. UNeMed has a diverse technology portfolio that addresses significant medical and clinical needs in areas such as Therapeutics, Diagnostics, Medical Devices, Research Tools and Software. For further information regarding UNeMed and its patent portfolio, please contact Dr. Michael J. Dixon (email@example.com).